2025 San Antonio Breast Cancer Symposium (SABCS 2025)

A recent China study has provided further evidence on the real-world efficacy and safety of sacituzumab govitecan (SG) in HR+/HER2- and triple-negative breast cancer (TNBC) patients who have received at least three lines of prior therapy.

An analysis using data from two large prospective studies demonstrates the protective effect of cruciferous vegetable consumption against breast cancer.

A real-world study of the antibody-drug conjugate (ADC) sacituzumab govitecan in patients with HR+/ HER2- metastatic breast cancer (mBC) or metastatic triple-negative breast cancer (mTNBC) shows consistent survival outcomes as those seen in clinical trials.

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).